Mood Stabilizers News and Research

RSS

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates, and other characteristics compared with those with major depression alone, research shows.

11 Oct 2012

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates and other characteristics compared with those with major depression alone, research shows.

10 Oct 2012

Study provides new direction for research in bipolar disorder during pregnancy

The impact of bipolar disorder during pregnancy has been hotly contended among the research community. Now, a new study from Lawson Health Research Institute and Western University is sorting out the debate and calling for more targeted, prospective research.

23 Aug 2012

Scientists discover biological marker that may help identify patients’ response to antidepressants

Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

7 Aug 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

New clinical research study to compare two medications for bipolar disorder

Patients with bipolar disorder may be eligible for a new clinical research study comparing two medications -- quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication, and lithium, the gold-standard mood stabilizer.

25 May 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Medication for depression ended before recommended time

Swedish women's use of antidepressants is twice as high as that of Swedish men. However, among both female and male new users, one fifth fills only one prescription. "This can be an indication of choices being made to end treatment before the recommended time," says researcher Karolina Andersson Sundell at the Nordic School of Public Health.

10 Dec 2010

Seaside Therapeutics reports positive data from STX209 Phase 2 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability -- a core symptom of fragile X syndrome.

26 Jul 2010

Intellectually disabled in Victorian government run facilities treated in a “Victorian” manner

A disturbing new report has revealed that nearly 150 patients with intellectual disabilities in Victoria’s Grampians and Loddon Mallee regions in the last financial year were restrained using chemical or mechanical means and often secluded.

10 May 2010

Antidepressants and mood stabilizers may benefit stroke victims

A study in rodents shows the growth of new neurons, also known as neurogenesis, lessens the severity of stroke and dramatically improves function following a stroke. The research, undertaken at the Buck Institute for Age Research, suggests that drugs shown to promote neurogenesis in rodents could have benefits for human stroke victims and that those drugs-which include antidepressants and mood stabilizers such as lithium-may be suitable for study in human clinical trials.

13 Apr 2010

Mood altering effects of Phenytoin

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties.

30 Mar 2010

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Cephalon announces positive results from study of NUVIGIL in bipolar depression

Cephalon, Inc. has announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder.

17 Mar 2009

New treatment approach needed for management of depression with bipolar disorder

In a study published in The American Journal of Psychiatry, a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-emergent mania (TEM).

15 Feb 2009

Bipolar disorders linked to increased risk of early death from medical illness

Bipolar disorders appear to increase the risk of early death from a medical illness, according to a literature review study published as the lead article this week in the journal Psychiatric Services.

2 Feb 2009

Study identifies problems with diagnosis of bipolar disorder

A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview--the Structured Clinical Interview for DSM-IV (SCID).

6 May 2008

Omega-3 fatty acids for bipolar disorder

Despite intriguing findings that omega-3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega-3s are useful treatments for people with bipolar disorder, according to a review of recent studies.

22 Apr 2008